Cullinan Therapeutics, Inc. Common Stock (CGEM)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Cullinan Therapeutics, Inc. Common Stock (CGEM) is listed on Nasdaq, where it has traded since January 8, 2021.
- Listed On
- Nasdaq
- Listed Since
- January 8, 2021
- Employees
- 109
- Market Cap
- $1.0B
About Cullinan Therapeutics, Inc. Common Stock
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 176 institutions reported holding CGEM, with 71.5 million shares worth $1.3 billion in aggregate. The largest reported holder was Mpm Bioimpact, with 9.7 million shares worth $177.2 million. Of the 5 largest holders listed below, 3 added shares and 2 held their positions unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Mpm Bioimpact | 9,731,341 | $177M | Added 27.24% |
| Lynx1 Capital Management | 8,963,500 | $163M | Unchanged |
| Bvf Inc/IL | 5,750,683 | $105M | Unchanged |
| BlackRock | 5,232,766 | $95M | Added 17.59% |
| T. Rowe Price | 3,825,950 | $70M | Added 88.5% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is CGEM?
Cullinan Therapeutics, Inc. Common Stock (CGEM) is listed on Nasdaq, where it has traded since January 8, 2021.
Who are the largest institutional holders of CGEM?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of CGEM were Mpm Bioimpact, Lynx1 Capital Management and Bvf Inc/IL.
How many institutions own CGEM?
176 institutions reported a position in CGEM for the quarter ended June 30, 2026, worth $1.3 billion in total.
Did institutions buy or sell CGEM last quarter?
Of the 5 largest reported holders, 3 added shares and 2 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for CGEM.
Every reported institutional holder, plus insider and congressional trades in CGEM, on SentiSense.